Friday, February 24, 2012 1:18:46 PM
What is "PDUFA " tia
Recent WINT News
- Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates • GlobeNewswire Inc. • 12/23/2025 02:00:00 PM
- Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space • GlobeNewswire Inc. • 12/03/2025 02:00:00 PM
- Windtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the Licensee • GlobeNewswire Inc. • 11/17/2025 02:00:00 PM
- Windtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent Estate • GlobeNewswire Inc. • 11/14/2025 02:00:00 PM
- Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company • GlobeNewswire Inc. • 11/13/2025 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2025 06:27:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/02/2025 09:16:05 PM
- Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting • GlobeNewswire Inc. • 09/02/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2025 04:15:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2025 09:29:07 PM
- Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025 • GlobeNewswire Inc. • 08/11/2025 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/08/2025 09:08:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:54:53 PM
- Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients • GlobeNewswire Inc. • 08/05/2025 01:00:00 PM
- Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption • GlobeNewswire Inc. • 07/29/2025 01:01:29 PM
- Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy • GlobeNewswire Inc. • 07/24/2025 01:00:00 PM
- Kraken and Windtree Therapeutics Announce Strategic Partnership for BNB Custody, Trading, and OTC Services • GlobeNewswire Inc. • 07/22/2025 01:00:00 PM
- Windtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On Subscriptions • GlobeNewswire Inc. • 07/16/2025 01:22:53 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/14/2025 04:15:09 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/10/2025 01:23:56 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/07/2025 08:55:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/03/2025 06:26:36 PM
- Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure • GlobeNewswire Inc. • 07/02/2025 01:00:00 PM
- Windtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim Analysis • GlobeNewswire Inc. • 06/30/2025 01:00:00 PM
- Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem’s Hormone-Free, On-Demand Prescription Contraceptive Gel • GlobeNewswire Inc. • 06/26/2025 08:05:00 PM
